Category Archives: Int’l Practice and Policy

Do You Really Want to File for Pharma Patent Protection in Canada, India or Ecuador?

Posted on February 15, 2018 by Warren Woessner

IPO Letter Reports Weaknesses in IP Protection Around the World In a 27 page letter dated February 8, 2018 and sent to Sue Chang at the Office of the U.S. Trade Representative, the Executive Director of IPO, Mark Lauroesch, extensively … Continue reading →

Posted in Govt Policy/PTO Policy, Int'l Practice and Policy, Non-U.S. Practice | Tagged , , | 1 Comment

Canada’s ‘’Sister” Prior Art Law Differs From Ours, Eh!

Posted on October 29, 2013 by Warren Woessner

I recently received a well-written post from Smart & Biggar/Feherstonhaugh in Toronto reminding me that a publication by the inventor only shields a later third-party publication from being a bar if the second publication was derived from the inventor and a … Continue reading →

Posted in Int'l Practice and Policy | Tagged , , , , , , , | Leave a comment

Review of Indian Working Requirements

Posted on August 21, 2013 by Warren Woessner

This newsletter (attached below) from a leading Indian firm, contains a good review of the perils of the working requirement in India. It also provides a good summary of three recent decisions holding pharma patents invalid for obviousness. What is striking is … Continue reading →

Posted in Int'l Practice and Policy | Tagged , , , , , , , , | Leave a comment

NOVARTIS A.G. v. UOI – What is Novelty in Indian Courts?

Posted on April 8, 2013 by Warren Woessner

Can everything old be made new again?  Lots has been written about the Indian Supreme Court rejecting a patent application claiming a crystal modification of imatinib mesylate (Gleevec), which is used to treat CML.  Novartis’ attempt to “evergreen” Gleevec with … Continue reading →

Posted in Int'l Practice and Policy, Obviousness | Tagged , , , , | Leave a comment